Genitourinary Cancer Special Issue 2019

Active surveillance has become the treatment of choice for low-risk prostate cancer, but new tools are needed to make it more precise.

In the medical community, we know that, at a population level, active surveillance is better for certain men with prostate cancer, so we believe the benefit weighs in their favor. We would like to offer men more certainty that surveillance can work for them and hope that, in the next few years, research will bring that to pass.

Drug duos that hit kidney cancer with immunotherapy and targeted treatment offer a better alternative to single agents.

We hope the information shared in these pages will be helpful to readers across the genitourinary cancer landscape, offering insights into the myriad treatments available and the issues to consider when choosing a therapeutic path.

Penile cancer can be a deeply personal and devastating disease, but catching it early can mean more tolerable treatment.

A variety of minimally invasive techniques can remove genitourinary tumors.